Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics demonstrated a 2.0-point ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of ...

(Reuters) -Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a ...

By Sriparna Roy (Reuters) -Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant ...

The new data – from the ARISE trial – found that Cobenfy wasn't statistically better than placebo at improving the widely ...

Bristol Myers Squibb's Cobenfy as an adjunctive treatment did not reach the threshold for a statistically significant difference compared to a placebo with an atypical antipsychotic in adults with ...

On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is ...

Neurocrine Biosciences' valbenazine shows promise as an adjunctive therapy for Schizophrenia, with phase 3 data expected in ...

In the Phase III ARISE trial, Cobenfy administered as an adjunctive treatment to atypical antipsychotics for patients with ...

The retina, as part of the central nervous system, may reflect early signs of brain disorders like schizophrenia.